Stuart Therapeutics adds recognized leaders in the development and commercialization of ophthalmic therapeutics.
Stuart, Florida., December 22, 2024 /PRNewswire/ — Stuart Therapeutics today announced its appointment Tracy Valory and Jason Werner To the company’s Board of Directors, bringing the total number of Board members to five. These new directors will fill the positions previously held Robert or ParathaMD, who passed away suddenly in the third quarter of this year, and a retired American actor Diane Black, RNShe recently resigned from her position on the company’s board of directors.
Tracy Valory He is a strategic business consultant and owner V Associates™ LLC since July 2019. Mrs. Valory He has 30 years of experience in the pharmaceutical and biotechnology industry. Mrs. Valory He served as Senior Vice President, General Manager of we Bausch + Lomb’s pharmaceutical and surgical businesses July 2012 to May 2019. Before joining B+L in 2012, Mrs. Valory He served as Commercial Leader for Ophthalmology at Pfizer a company. (NYSE: NYSE:) where she had global responsibility for the ophthalmic brands as well as responsibility for mid-stage portfolio commercial development and long-term strategic planning. She currently serves as an advisor or board member for several startups and was recently appointed to a board of directors Directors of the Glaucoma Research Foundation (GRF). Mrs. Valory He holds a Master’s degree in Business Administration from Rensselaer Polytechnic Institute Bachelor of Science in Molecular Biology from University of Connecticut in Storrs, C.T.
Jason Werner He currently serves as CEO of Sightstream Biotherapeutics, a biotechnology company focused on developing regenerative therapies in ophthalmology, and is a member of the Board of Directors of InflammX Therapeutics. In addition, Mr. Werner He served as a Director of Alimera (NASDAQ:) since Q2 2023 before joining the Alimera management team in Q4 2023 and subsequently helping lead the company through its recent sale to ANI Pharma in Q4 2024. Mr. Werner He previously co-founded and served as its chief operating officer Evans Pharmaceutical Industries From the founding of the company until its sale Santen Pharmaceuticals Co., Ltd He has also held a variety of commercial development and corporate strategy roles at companies such as Sun Pharma, Nikox (EPA:) SA and Pharmaceutical inspirationall in the field of ophthalmology. Mr. Werner He obtained a bachelor’s degree in business administration from University of New Hampshire.
“We are excited about the opportunity to have Tracy and Jason on board as members of our board of directors and senior advisors to Stuart Therapeutics as we move into the next phase of development and commercialization in ophthalmic therapeutics,” he said. Eric Smurf, Stuart President and CEO. “Our team will benefit from the successful experiences they bring to our organization. We would also like to acknowledge the contributions of our friend and co-founder Pop ParathaMD, and Diane Black, RN“They played an instrumental role in guiding the company through its formative stages, and we wish Diane success in her future endeavours.”
“I am thrilled to join the board of Stuart Therapeutics. The opportunity to contribute to such an innovative biotech company at the forefront of groundbreaking therapies is truly exciting. I look forward to collaborating with a great team, to help guide the company as it grows,” he said. “Looking forward to making a difference.” Measurable impact on the lives of patients diagnosed with underserved eye disorders.” Tracy Valory.
Jason Werner “This is an exciting time for Stuart Therapeutics with key development and pipeline milestones on the horizon,” he said. “I look forward to working alongside Tracy, Eric and the rest of the talented team to help ensure these new therapies reach patients while maximizing shareholder value.” Stuart And its investors.
on Stewart Therapeutics, Inc
Stewart Therapeutics, Inc is a clinical-stage ophthalmology therapeutic development company, headquartered in Stuart, Florida. The company’s lead asset, ST-100, is in the final stages of its Phase 3 clinical trial, with readouts expected in the first quarter of 2025. Stuart It is also developing pioneering programs in retinal diseases and myopia and has a development partnership through a neuroprotection license in glaucoma with Glacos Company (New York Stock Exchange:). to Aliso Viejo, California.
Media Contact:
Eric Smurf
President and CEO
eric@stuarttherapeutics.com
206-228-2781
www.stuarttherapeutics.com
